BioSpace News Archive

Achilles Therapeutics plc announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, announced that the Company will participate in fireside chats at the following upcoming investor events.

Celcuity Inc., a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.

Olema Pharmaceuticals, Inc. announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Annual Congress 2024 taking place May 15-17, 2023, in Berlin, Germany.

CRISPR Therapeutics announced new preclinical data presented at the 27th Annual Meeting of the American Society of Cell and Gene Therapy highlighting the Company’s approach to developing lipid nanoparticle based delivery for in vivo ocular gene editing.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease, a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain, an ocular condition associated with pain but without an FDA approved therapy, announced upcoming presentations at two investor conferences in May 2024.

Acepodia announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma.

Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York Barclay in New York, NY.

Aldeyra Therapeutics, Inc. announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.